Who owns Zenas BioPharma, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ZBIO from SEC Form 13F filings across 153 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 153 institutions disclosed 68.1M shares of Zenas BioPharma, Inc. worth $1.84B — about 103% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
153
13F holders
$1.84B
value, 2026 filers
103%
of shares outstanding (68.1M sh)
24
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ZBIO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.8M | $264.1M | 0.0% | 14.8% | +3.0% |
| 2 | WELLINGTON MANAGEMENT GROUP LLP | 8.1M | $218.3M | 0.0% | 12.2% | +407.9% |
| 3 | SR ONE CAPITAL MANAGEMENT, LP | 5.0M | $135.9M | 11.8% | 7.6% | 0.0% |
| 4 | NEA Management Company, LLC | 4.0M | $108.5M | 8.0% | 6.1% | 0.0% |
| 5 | BlackRock, Inc. | 3.3M | $89.9M | 0.0% | 5% | +24.1% |
| 6 | FEDERATED HERMES, INC. | 3.1M | $83.8M | 0.1% | 4.7% | -0.3% |
| 7 | Capital International Investors | 2.9M | $78.9M | 0.0% | 4.4% | +16.9% |
| 8 | ENAVATE SCIENCES GP, LLC | 2.9M | $78.7M | 28.1% | 4.4% | -25.5% |
| 9 | Polar Capital Holdings Plc | 2.4M | $64.9M | 0.2% | 3.6% | -0.3% |
| 10 | Royalty Pharma Sub-Manager, LLC | 2.4M | $64.4M | 32.8% | 3.6% | 0.0% |
| 11 | Fairmount Funds Management LLC | 2.4M | $64.0M | 4.0% | 3.6% | +0.5% |
| 12 | STATE STREET CORP | 1.9M | $50.8M | 0.0% | 2.8% | -8.4% |
| 13 | NVP ASSOCIATES, LLC | 1.8M | $49.6M | 17.6% | 2.8% | 0.0% |
| 14 | VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $46.5M | 0.0% | 2.6% | +27.1% |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.1M | $29.3M | 0.0% | 1.6% | -11.3% |
| 16 | ALLIANCEBERNSTEIN L.P. | 1.1M | $28.6M | 0.0% | 1.6% | -3.9% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $28.6M | 0.0% | 1.6% | +20.1% |
| 18 | TWO SIGMA INVESTMENTS, LP | 833,288 | $22.5M | 0.0% | 1.3% | +2.2% |
| 19 | EcoR1 Capital, LLC | 789,500 | $21.3M | 0.9% | 1.2% | 0.0% |
| 20 | GOLDMAN SACHS GROUP INC | 774,621 | $20.9M | 0.0% | 1.2% | +185.7% |
| 21 | BANK OF AMERICA CORP /DE/ | 683,308 | $18.4M | 0.0% | 1% | -44.5% |
| 22 | Candriam S.C.A.NEW | 654,833 | $17.7M | 0.1% | 1% | new |
| 23 | Woodline Partners LP | 590,969 | $15.9M | 0.0% | 0.9% | +0.1% |
| 24 | ArrowMark Colorado Holdings LLC | 527,976 | $14.2M | 0.7% | 0.8% | -7.9% |
| 25 | Rock Springs Capital Management LP | 502,077 | $13.5M | 0.7% | 0.8% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.